Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG-N0377, Alliance).

CONCLUSION: Everolimus does not have sufficient single-agent activity in MM; however, we have identified evidence of biological activity to provide a potential rationale for future combination studies.
PMID: 29666297 [PubMed - as supplied by publisher]

Source: The Oncologist - April 17, 2018 Category: Cancer & Oncology Authors: Vera Aguilera J, Rao RD, Allred JB, Suman VJ, Windschitl HE, Kaur JS, Maples WJ, Lowe VJ, Creagan ET, Erickson LA, Markovic S Tags: Oncologist Source Type: research